Docetaxel as Second Line After Failure of Gemcitabine/Cisplatin Regimen in Advanced and/or Metastatic Urinary Bladder Cancer Patients in Egypt

Research in Oncology

doi 10.21608/resoncol.2013.881

Full Text

Abstract

Available in

Date

November 1, 2013

Authors

Engi Elkholy

Mai Ezz El Din

Publisher

Egypts Presidential Specialized Council for Education and Scientific Research

Related search

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced and or Metastatic Bilharzial Urothelial Carcinoma of the Bladder in Egypt.

Research in Oncology

2011

English

Triplet Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin as Second-Line Therapy for Advanced Urothelial Carcinoma

Modern Chemotherapy

2013

English

Biweekly Cisplatin and Gemcitabine in Patients With Advanced Biliary Tract Cancer

International Journal of Cancer

Cancer Research

Oncology

2017

English

Triplet Chemotherapy Combination With Cisplatin, Gemcitabine and Docetaxel in Patients With Chemotherapy‑naive Advanced Non-Small Cell Lung Cancer

English

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine

Internal Medicine

2007

English

Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

British Journal of Cancer

Cancer Research

Oncology

2018

English

An Open-Label Feasibility Study of Nintedanib Combined With Docetaxel in Japanese Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of First-Line Chemotherapy

Cancer Chemotherapy and Pharmacology

English

Efficacy of Fluoropyrimidine-Based Chemotherapy in Patients With Advanced Biliary Tract Cancer After Failure of Gemcitabine Plus Cisplatin: Retrospective Analysis of 321 Patients

British Journal of Cancer

Cancer Research

Oncology

2017

English

Gemcitabine Combined With Capecitabine Compared to Gemcitabine With or Without Erlotinib as First-Line Chemotherapy in Patients With Advanced Pancreatic Cancer

Cancer Research and Treatment

Cancer Research

Oncology

2014

English

Amanote Research

Docetaxel as Second Line After Failure of Gemcitabine/Cisplatin Regimen in Advanced and/or Metastatic Urinary Bladder Cancer Patients in Egypt

Research in Oncology

Full Text

Abstract

Date

Authors

Publisher

Related search

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced and or Metastatic Bilharzial Urothelial Carcinoma of the Bladder in Egypt.

Triplet Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin as Second-Line Therapy for Advanced Urothelial Carcinoma

Biweekly Cisplatin and Gemcitabine in Patients With Advanced Biliary Tract Cancer

Triplet Chemotherapy Combination With Cisplatin, Gemcitabine and Docetaxel in Patients With Chemotherapy‑naive Advanced Non-Small Cell Lung Cancer

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

An Open-Label Feasibility Study of Nintedanib Combined With Docetaxel in Japanese Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of First-Line Chemotherapy

Efficacy of Fluoropyrimidine-Based Chemotherapy in Patients With Advanced Biliary Tract Cancer After Failure of Gemcitabine Plus Cisplatin: Retrospective Analysis of 321 Patients

Gemcitabine Combined With Capecitabine Compared to Gemcitabine With or Without Erlotinib as First-Line Chemotherapy in Patients With Advanced Pancreatic Cancer